Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Sci. 2021. 112. 12. 5020-5033
Aoki T, Narita Y, Mishima K, Matsutani M. Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan. Neurol Med Chir (Tokyo). 2020. 60. 12. 600-611
Mishima K, Narita Y, Nagane M, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, et al. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology. 2020. 22. Supplement 2. ii57-ii58
A Peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
2000 -